News & Updates
Filter by Specialty:
Male sex, obesity among risk factors for severe COVID-19 in children
A large study by the US National COVID Cohort Collaborative (N3C) has identified factors associated with the risk of severe disease among children with SARS-CoV-2 infection as well as factors tied to an increased risk of multisystem inflammatory syndrome in children (MIS-C) as compared to acute COVID-19.
Male sex, obesity among risk factors for severe COVID-19 in children
20 May 2022
Antidepressant exposure in pregnancy not a risk factor for neonatal seizures, epilepsy
In pregnant women, the use of serotonergic antidepressants does not appear to put babies at risk of developing seizures or epilepsy, as reported in a study.
Antidepressant exposure in pregnancy not a risk factor for neonatal seizures, epilepsy
20 May 2022
Infliximab does not contribute to long-term weight gain in IBD patients
Treatment with infliximab does not lead to a general long-term weight gain in patients with inflammatory bowel disease (IBD), claims a study.
Infliximab does not contribute to long-term weight gain in IBD patients
20 May 2022
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
20 May 2022
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
Patients who have had a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are likely to experience a recurrent ischaemic stroke episode and bleeding, according to data from the RENO-EXTEND Study.
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
20 May 2022
Sustained benefits with ocrelizumab in relapsing-remitting MS
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
